Verve Therapeutics Dividende
Dividende contrôle des critères 0/6
Verve Therapeutics does not have a record of paying a dividend.
Informations clés
n/a
Rendement du dividende
-46.6%
Rendement des rachats
| Rendement total pour l'actionnaire | -46.6% |
| Rendement futur des dividendes | 0% |
| Croissance des dividendes | n/a |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | n/a |
Mises à jour récentes des dividendes
Pas de mise à jour
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Insufficient data to determine if VERV's dividends per share have been stable in the past.
Dividende croissant: Insufficient data to determine if VERV's dividend payments have been increasing.
Rendement des dividendes par rapport au marché
| Verve Therapeutics Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (VERV) | n/a |
| 25% du marché (US) | 1.5% |
| 25% du marché (US) | 4.5% |
| Moyenne du secteur (Biotechs) | 2.2% |
| Analyste prévisionnel (VERV) (jusqu'à 3 ans) | 0% |
Dividende notable: Unable to evaluate VERV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividende élevé: Unable to evaluate VERV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Bénéfice distribué aux actionnaires
Couverture des revenus: Insufficient data to calculate VERV's payout ratio to determine if its dividend payments are covered by earnings.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as VERV has not reported any payouts.